Advertisement

Continued Versus Interrupted Oral Anticoagulation During Transfemoral Transcatheter Aortic Valve Implantation and Impact of Postoperative Anticoagulant Management on Outcome in Patients With Atrial Fibrillation

Published:January 07, 2019DOI:https://doi.org/10.1016/j.amjcard.2018.12.042
      The role of continued versus interrupted oral anticoagulation (OAC) in patients with atrial fibrillation (AF) who underwent transfemoral transcatheter aortic valve implantation (TF-TAVI) for severe aortic stenosis is uncertain. The aim of this retrospective investigation was to evaluate the impact (1) of continued versus interrupted OAC on early safety and (2) of postoperative anticoagulant management on the 1-year mortality in patients with AF who underwent TF-TAVI. Consecutive patients with AF and on OAC at admission (n = 598) were stratified according to interrupted (iVKA) versus continued vitamin K antagonist (cVKA) versus continued direct oral anticoagulants (DOAC) at the time of TF-TAVI. Valve Academic Research Consortium-2 early safety was the primary outcome measure. Patients with iVKA (n = 299), cVKA (n = 117), and DOAC (n = 182) had comparable baseline characteristics including age (p = 0.25), gender (p = 0.33), and STS-Score (p = 0.072). The proportion of patients having a CHA2DS2-VASc-Score ≥3 (p = 0.791) and HAS-BLED-Score ≥3 (p = 0.185) was not different between groups. The rate of early safety events (with lower values indicating superior safety) was lowest in DOAC (13.2%) and not increased in cVKA (19.7%) compared to iVKA (23.1%) (p = 0.029). Valve Academic Research Consortium-2 defined stroke (p = 0.527) and bleeding (p = 0.097) did not differ between groups. Renal failure occurred more often in iVKA compared to cVKA and DOAC (p = 0.02). All-cause 1-year mortality was 20.1% in iVKA, 13.7% in cVKA, and 8.8% in DOAC (p = 0.015). Multivariate analysis revealed DOAC to be associated with reduced all-cause 1-year mortality (HR 0.56 (95%-CI 0.32 to 0.99), p = 0.047) whereas cVKA was comparable to iVKA (HR 0.75 (95%-CI 0.43 to 1.31), p = 0.307). In conclusion, cVKA did not increase the rate for the composite end point of early safety at 30 days in this cohort of patients. Treatment with a DOAC was associated with a significantly reduced rate of early safety end points at 30 days and lower 1-year mortality.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Steine K
        • Rossebo AB
        • Stugaard M
        • Pedersen TR
        Left ventricular systolic and diastolic function in asymptomatic patients with moderate aortic stenosis.
        Am J Cardiol. 2008; 102: 897-901
        • Greve AM
        • Gerdts E
        • Boman K
        • Gohlke-Baerwolf C
        • Rossebo AB
        • Nienaber CA
        • Ray S
        • Egstrup K
        • Pedersen TR
        • Kober L
        • Willenheimer R
        • Wachtell K
        Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
        Int J Cardiol. 2013; 166: 72-76
        • Schulenberg R
        • Antonitsis P
        • Stroebel A
        • Westaby S
        Chronic atrial fibrillation is associated with reduced survival after aortic and double valve replacement.
        Ann Thorac Surg. 2010; 89: 738-744
        • Tarantini G
        • Mojoli M
        • Urena M
        • Vahanian A
        Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome.
        Eur Heart J. 2017; 38: 1285-1293
        • Smith CR
        • Leon MB
        • Mack MJ
        • Miller DC
        • Moses JW
        • Svensson LG
        • Tuzcu EM
        • Webb JG
        • Fontana GP
        • Makkar RR
        • Williams M
        • Dewey T
        • Kapadia S
        • Babaliaros V
        • Thourani VH
        • Corso P
        • Pichard AD
        • Bavaria JE
        • Herrmann HC
        • Akin JJ
        • Anderson WN
        • Wang D
        • Pocock SJ
        Transcatheter versus surgical aortic-valve replacement in high-risk patients.
        N Engl J Med. 2011; 364: 2187-2198
        • Leon MB
        • Smith CR
        • Mack MJ
        • Makkar RR
        • Svensson LG
        • Kodali SK
        • Thourani VH
        • Tuzcu EM
        • Miller DC
        • Herrmann HC
        • Doshi D
        • Cohen DJ
        • Pichard AD
        • Kapadia S
        • Dewey T
        • Babaliaros V
        • Szeto WY
        • Williams MR
        • Kereiakes D
        • Zajarias A
        • Greason KL
        • Whisenant BK
        • Hodson RW
        • Moses JW
        • Trento A
        • Brown DL
        • Fearon WF
        • Pibarot P
        • Hahn RT
        • Jaber WA
        • Anderson WN
        • Alu MC
        • Webb JG
        Transcatheter or surgical aortic-valve replacement in intermediate-risk patients.
        N Engl J Med. 2016; 374: 1609-1620
        • Linke A
        • Schlotter F
        • Haussig S
        • Woitek FJ
        • Stachel G
        • Adam J
        • Hollriegel R
        • Lindner A
        • Mohr FW
        • Schuler G
        • Kiefer P
        • Leontyev S
        • Thiele H
        • Borger MA
        • Holzhey D
        • Mangner N
        Gender-dependent association of diabetes mellitus with mortality in patients undergoing transcatheter aortic valve replacement.
        Clin Res Cardiol. 2018; https://doi.org/10.1007/s00392-018-1309-0
        • Mangner N
        • Woitek F
        • Haussig S
        • Schlotter F
        • Stachel G
        • Hollriegel R
        • Wilde J
        • Lindner A
        • Holzhey D
        • Leontyev S
        • Mohr FW
        • Schuler G
        • Linke A
        Incidence, predictors, and outcome of patients developing infective endocarditis following transfemoral transcatheter aortic valve replacement.
        J Am Coll Cardiol. 2016; 67: 2907-2908
        • Mangner N
        • Stachel G
        • Woitek F
        • Haussig S
        • Schlotter F
        • Hollriegel R
        • Adam J
        • Lindner A
        • Mohr FW
        • Schuler G
        • Kiefer P
        • Leontyev S
        • Borger MA
        • Thiele H
        • Holzhey D
        • Linke A
        Predictors of mortality and symptomatic outcome of patients with low-flow severe aortic stenosis undergoing transcatheter aortic valve replacement.
        J Am Heart Assoc. 2018; 7: e007977
        • Mangner N
        • Woitek FJ
        • Haussig S
        • Holzhey D
        • Stachel G
        • Schlotter F
        • Hollriegel R
        • Mohr FW
        • Schuler G
        • Linke A
        Impact of active cancer disease on the outcome of patients undergoing transcatheter aortic valve replacement.
        J Interv Cardiol. 2018; 31: 188-196
        • Chen ST
        • Patel MR
        Comparison of anticoagulant therapy for atrial fibrillation—novel oral anticoagulants versus vitamin K antagonists.
        Prog Cardiovasc Dis. 2018; 60: 514-523
        • Connolly SJ
        • Ezekowitz MD
        • Yusuf S
        • Eikelboom J
        • Oldgren J
        • Parekh A
        • Pogue J
        • Reilly PA
        • Themeles E
        • Varrone J
        • Wang S
        • Alings M
        • Xavier D
        • Zhu J
        • Diaz R
        • Lewis BS
        • Darius H
        • Diener HC
        • Joyner CD
        • Wallentin L
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Giugliano RP
        • Ruff CT
        • Braunwald E
        • Murphy SA
        • Wiviott SD
        • Halperin JL
        • Waldo AL
        • Ezekowitz MD
        • Weitz JI
        • Spinar J
        • Ruzyllo W
        • Ruda M
        • Koretsune Y
        • Betcher J
        • Shi M
        • Grip LT
        • Patel SP
        • Patel I
        • Hanyok JJ
        • Mercuri M
        • Antman EM
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Granger CB
        • Alexander JH
        • McMurray JJ
        • Lopes RD
        • Hylek EM
        • Hanna M
        • Al-Khalidi HR
        • Ansell J
        • Atar D
        • Avezum A
        • Bahit MC
        • Diaz R
        • Easton JD
        • Ezekowitz JA
        • Flaker G
        • Garcia D
        • Geraldes M
        • Gersh BJ
        • Golitsyn S
        • Goto S
        • Hermosillo AG
        • Hohnloser SH
        • Horowitz J
        • Mohan P
        • Jansky P
        • Lewis BS
        • Lopez-Sendon JL
        • Pais P
        • Parkhomenko A
        • Verheugt FW
        • Zhu J
        • Wallentin L
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Patel MR
        • Mahaffey KW
        • Garg J
        • Pan G
        • Singer DE
        • Hacke W
        • Breithardt G
        • Halperin JL
        • Hankey GJ
        • Piccini JP
        • Becker RC
        • Nessel CC
        • Paolini JF
        • Berkowitz SD
        • Fox KA
        • Califf RM
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Di BL
        • Burkhardt JD
        • Santangeli P
        • Mohanty P
        • Sanchez JE
        • Horton R
        • Gallinghouse GJ
        • Themistoclakis S
        • Rossillo A
        • Lakkireddy D
        • Reddy M
        • Hao S
        • Hongo R
        • Beheiry S
        • Zagrodzky J
        • Rong B
        • Mohanty S
        • Elayi CS
        • Forleo G
        • Pelargonio G
        • Narducci ML
        • Dello RA
        • Casella M
        • Fassini G
        • Tondo C
        • Schweikert RA
        • Natale A
        Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.
        Circulation. 2014; 129: 2638-2644
        • Douketis JD
        • Spyropoulos AC
        • Kaatz S
        • Becker RC
        • Caprini JA
        • Dunn AS
        • Garcia DA
        • Jacobson A
        • Jaffer AK
        • Kong DF
        • Schulman S
        • Turpie AG
        • Hasselblad V
        • Ortel TL
        Perioperative bridging anticoagulation in patients with atrial fibrillation.
        N Engl J Med. 2015; 373: 823-833
        • Calkins H
        • Willems S
        • Gerstenfeld EP
        • Verma A
        • Schilling R
        • Hohnloser SH
        • Okumura K
        • Serota H
        • Nordaby M
        • Guiver K
        • Biss B
        • Brouwer MA
        • Grimaldi M
        Uninterrupted Dabigatran versus Warfarin for ablation in atrial fibrillation.
        N Engl J Med. 2017; 376: 1627-1636
        • Roques F
        • Nashef SA
        • Michel P
        • Gauducheau E
        • de VC
        • Baudet E
        • Cortina J
        • David M
        • Faichney A
        • Gabrielle F
        • Gams E
        • Harjula A
        • Jones MT
        • Pintor PP
        • Salamon R
        • Thulin L
        Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients.
        Eur J Cardiothorac Surg. 1999; 15: 816-822
        • O'Brien SM
        • Shahian DM
        • Filardo G
        • Ferraris VA
        • Haan CK
        • Rich JB
        • Normand SL
        • DeLong ER
        • Shewan CM
        • Dokholyan RS
        • Peterson ED
        • Edwards FH
        • Anderson RP
        The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2–isolated valve surgery.
        Ann Thorac Surg. 2009; 88: S23-S42
        • Kirchhof P
        • Benussi S
        • Kotecha D
        • Ahlsson A
        • Atar D
        • Casadei B
        • Castella M
        • Diener HC
        • Heidbuchel H
        • Hendriks J
        • Hindricks G
        • Manolis AS
        • Oldgren J
        • Popescu BA
        • Schotten U
        • Van PB
        • Vardas P
        2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37: 2893-2962
        • Kappetein AP
        • Head SJ
        • Genereux P
        • Piazza N
        • Van Mieghem NM
        • Blackstone EH
        • Brott TG
        • Cohen DJ
        • Cutlip DE
        • van Es GA
        • Hahn RT
        • Kirtane AJ
        • Krucoff MW
        • Kodali S
        • Mack MJ
        • Mehran R
        • Rodes-Cabau J
        • Vranckx P
        • Webb JG
        • Windecker S
        • Serruys PW
        • Leon MB
        Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.
        J Am Coll Cardiol. 2012; 60: 1438-1454
        • Wang J
        • Yu W
        • Zhou Y
        • Yang Y
        • Li C
        • Liu N
        • Hou X
        • Wang L
        Independent risk factors contributing to acute kidney injury according to updated valve academic research consortium-2 criteria after transcatheter aortic valve implantation: a meta-analysis and meta-regression of 13 studies.
        J Cardiothorac Vasc Anesth. 2017; 31: 816-826
        • Seeger J
        • Gonska B
        • Rodewald C
        • Rottbauer W
        • Wohrle J
        Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement.
        JACC Cardiovasc Interv. 2017; 10: 66-74
        • Lee CJ
        • Gerds TA
        • Carlson N
        • Bonde AN
        • Gislason GH
        • Lamberts M
        • Olesen JB
        • Pallisgaard JL
        • Hansen ML
        • Torp-Pedersen C
        Risk of myocardial infarction in anticoagulated patients with atrial fibrillation.
        J Am Coll Cardiol. 2018; 72: 17-26
        • Eikelboom Jw
        • Connolly SJ
        • Brueckmann M
        • Granger CB
        • Kappetein AP
        • Mack MJ
        • Blatchford J
        • Devenny K
        • Friedman J
        • Guiver K
        • Harper R
        • Khder Y
        • Lobmeyer MT
        • Maas H
        • Voigt JU
        • Simoons ML
        • Van de Werf F
        Dabigatran versus warfarin in patients with mechanical heart valves.
        N Engl J Med. 2013; 369: 1206-1214
        • Yadlapati A
        • Groh C
        • Malaisrie SC
        • Gajjar M
        • Kruse J
        • Meyers S
        • Passman R
        Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves.
        Clin Res Cardiol. 2016; 105: 268-272
        • Collet JP
        • Berti S
        • Cequier A
        • Van BE
        • Lefevre T
        • Leprince P
        • Neumann FJ
        • Vicaut E
        • Montalescot G
        Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial.
        Am Heart J. 2018; 200: 44-50
        • Windecker S
        • Tijssen J
        • Giustino G
        • Guimaraes AH
        • Mehran R
        • Valgimigli M
        • Vranckx P
        • Welsh RC
        • Baber U
        • van Es GA
        • Wildgoose P
        • Volkl AA
        • Zazula A
        • Thomitzek K
        • Hemmrich M
        • Dangas GD
        Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
        Am Heart J. 2017; 184: 81-87
        • Rogers T
        • Koifman E
        • Patel N
        • Gai J
        • Torguson R
        • Corso P
        • Waksman R
        Society of Thoracic Surgeons Score variance results in risk reclassification of patients undergoing transcatheter aortic valve replacement.
        JAMA Cardiol. 2017; 2: 455-456